Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price target on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th.

Minerva Neurosciences Price Performance

Shares of NERV opened at $2.62 on Friday. Minerva Neurosciences has a 12 month low of $2.26 and a 12 month high of $13.49. The stock’s 50-day moving average is $2.66 and its two-hundred day moving average is $2.80. The stock has a market cap of $18.31 million, a PE ratio of -0.59 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). On average, research analysts anticipate that Minerva Neurosciences will post -2.26 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.